Fidelity Advisor Biotechnology C (FBTCX)

Fund Assets	2.43B
Expense Ratio	1.647%
Min. Investment	$0.00
Turnover	54.00%
Dividend (ttm)	0.39
Dividend Yield	1.05%
Dividend Growth	-36.26%
Payout Frequency	n/a
Ex-Dividend Date	Dec 26, 2025

Previous Close	35.67
YTD Return	27.59%
1-Year Return	41.14%
5-Year Return	60.42%
52-Week Low	26.61
52-Week High	39.90
Beta (5Y)	0.84
Holdings	131
Inception Date	Dec 27, 2000

About FBTCX

Fidelity Advisor Biotechnology Fund Class C is a mutual fund that primarily invests in companies within the biotechnology sector. Its central objective is capital appreciation, achieved by allocating at least 80% of its assets to securities of firms engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. The fund is notably concentrated in the healthcare industry, focusing on businesses that benefit significantly from advances in biotechnology, such as pharmaceuticals and innovative therapeutic providers. The portfolio often holds a high percentage of assets in its top holdings, which typically include leading biotechnology and pharmaceutical companies. With total assets exceeding $1.3 billion, the fund plays a prominent role in offering investors exposure to the dynamic and innovation-driven field of biotechnology. The fund’s investment style is characterized as “mid-blend,” and it is managed with an emphasis on capturing the growth potential within the sector while balancing risk through diversified holdings of both large and emerging biotech firms. This fund is part of Fidelity’s suite of sector-specific offerings, serving investors seeking targeted access to the biotechnology market.

• Fund Family: Fidelity
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Above Average
• Stock Exchange: Nasdaq
• Ticker Symbol: FBTCX
• Share Class: Class C
• Index: S&P 500 TR

Performance

FBTCX had a total return of 41.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.85%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FIJYX	Class Z	0.57%
FBTIX	Class I	0.69%
FBTAX	Class A	0.94%
FBTTX	Class M	1.19%

Top 10 Holdings

46.21% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	13.83%
Gilead Sciences, Inc.	GILD	6.02%
Alnylam Pharmaceuticals, Inc.	ALNY	3.84%
Insmed Incorporated	INSM	3.41%
Amylyx Pharmaceuticals, Inc.	AMLX	3.38%
argenx SE	ARGX	3.28%
Dianthus Therapeutics, Inc.	DNTH	3.18%
Spyre Therapeutics, Inc.	SYRE	3.16%
Moderna, Inc.	MRNA	3.12%
Revolution Medicines, Inc.	RVMD	2.98%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 26, 2025	$0.483	Dec 29, 2025
Dec 26, 2024	$1.441	Dec 27, 2024
Dec 17, 2021	$5.241	Dec 20, 2021
Jul 9, 2021	$0.006	Jul 12, 2021
Dec 18, 2020	$2.732	Dec 21, 2020
Dec 20, 2019	$1.849	Dec 23, 2019

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Nov 9, 2026

Data Sources Report a data error